Published: December 2011

Prescriber Update Quiz 2011

Prescriber Update 32(4): 40
December 2011

Have you read your copy of Prescriber Update in 2011?
Have you kept up to date with emerging safety signals?

Test your knowledge with the end of year Prescriber Update quiz.

Answers to the quiz are available at:

  1. Rosiglitazone was removed from the market in New Zealand because of
    1. An increased risk of bladder cancer
    2. The cost of treatment
    3. An increased risk of myocardial infarction
    4. An increased risk of pancreatitis
  2. Name the three medicines currently on the M² logo medicines monitoring programme
  3. Cough and cold medicines are contraindicated in which group?
    1. Elderly patients over 80 years
    2. Children under 12 years of age
    3. Children under 6 years of age
    4. For the treatment of "man-flu"
  4. How can paroxetine reduce the effectiveness of tamoxifen?
    1. By reducing the absorption of tamoxifen
    2. By inhibiting CYP2D6 - an enzyme involved in the production of an active metabolite of tamoxifen
    3. Because paroxetine promotes cell growth
    4. By inducing the metabolism and clearance of tamoxifen
  5. Which CYP3A4 inhibitor increases the risk of patients experiencing an adverse reactions with statins:
    1. Erythromycin
    2. Fluconazole
    3. Ciclosporin
    4. Amiodarone
  6. The maximum recommended dose of simvastatin in New Zealand is now:
    1. 20 mg daily
    2. 40 mg daily
    3. 80 mg daily
    4. 160 mg daily
  7. The recommended dose of dabigratran in patients with atrial fibrillation who are considered at risk of bleeding (ie elderly, concomitant anticoagulants) is:
    1. 150 mg twice daily
    2. 150 mg once daily
    3. 110 mg twice daily
    4. 75 mg once daily
  8. True or false:  dabigatran is contraindicated in patients with severe renal impairment (< 30 ml/min CrCl)
  9. Name two medicines associated with drug-induced glaucoma.
  10. True or false: SSRIs do not increase the risk of bleeding.